Alkermes plc (NASDAQ: ALKS) is a Dublin, Ireland-headquartered (US operations principally in Waltham, Massachusetts) biopharmaceutical company focused on central-nervous-system (CNS) diseases — developing and commercializing therapies for psychiatric conditions (schizophrenia, bipolar disorder), addiction (opioid and alcohol dependence), and sleep/wakefulness disorders (narcolepsy). The company was founded in 1987 by Richard Pops (Chairman, President & CEO — one of the longest-tenured CEOs in biotech) and has evolved through multiple strategic transformations: a 1990s/2000s focus on drug-delivery technology (long-acting injectable / sustained-release platforms), a 2011 reverse merger with Elan Drug Technologies establishing the current Irish-headquartered structure, a multi-year build of a commercial-stage CNS franchise (VIVITROL launched 2006, ARISTADA 2015, LYBALVI 2021), an oncology-development push that was spun off in late 2023 as Mural Oncology (MURA) to refocus Alkermes as a pure-play CNS company, and the 2022-2024 monetization of various royalty streams (including Sandoz/Aristada-related royalties) generating substantial cash. Today Alkermes runs a focused commercial CNS portfolio plus a CNS-focused pipeline, with the headline pipeline asset ALKS 2680 — an oral orexin-2 receptor agonist for narcolepsy. Capital structure is net-cash with minimal debt and aggressive buyback / capital-return activity. Geography is US-led commercial with selected ex-US partnered. ALKS enters FY2026 with FY2025 revenue selected various aggregate ~$1.55-1.85B, aggregate adjusted EPS ~$2.80-3.50, adjusted EBITDA ~$380-470M (~22-26% margin), under Pops. The first thesis pillar is the commercial CNS franchise — three approved products generating ~$1.1-1.3B+ annually: VIVITROL (extended-release naltrexone, monthly IM, opioid/alcohol dependence — launched 2006, ~$430-490M+, low-single-digit % growth — used in addiction-treatment centers, behavioral-health clinics, drug courts, prison systems, primary care/OBGYN; growth driven by opioid epidemic + LAI-injection advantage vs daily oral naltrexone); ARISTADA (aripiprazole lauroxil, LAI in monthly/bi-monthly/every-2-month options for schizophrenia — launched 2015, ~$330-400M+, low-to-mid-single % growth — competing in the schizophrenia LAI market vs Otsuka/Lundbeck Abilify Maintena, Janssen Invega franchise, Sandoz Risperdal Consta, and generics; differentiates on dosing intervals and aripiprazole-lauroxil pro-drug profile); LYBALVI (oral olanzapine/samidorphan combination for schizophrenia + bipolar I — launched 2021, ~$310-400M+ growing fastest at mid-teens-to-twenties % as long-tail-of-launch plays out — designed to provide olanzapine's strong antipsychotic efficacy while reducing the substantial weight-gain side-effect that has historically limited olanzapine's use, addressing a real unmet need); FY2025 dynamics are VIVITROL/ARISTADA growing steadily, LYBALVI accelerating, gross-to-net stabilizing, operating leverage improving; FY2026 catalyst is LYBALVI prescription growth (leading-edge driver), VIVITROL/ARISTADA share defense, payer/formulary dynamics, generic-aripiprazole pressure on ARISTADA, and operating-margin expansion; risks/competitors are generic competition (LAI mechanisms partially insulate ARISTADA and VIVITROL but pricing pressure persists), newer antipsychotics — especially Bristol-Myers's Cobenfy (KarXT/xanomeline-trospium for schizophrenia approved 2024 — new mechanism competing with antipsychotic class), Otsuka's Rexulti, Janssen's Invega franchise, AbbVie — payer/formulary access, addiction-treatment-system funding fluctuations. The second pillar is ALKS 2680 plus the broader pipeline — the growth optionality: the narcolepsy opportunity — narcolepsy type 1 (NT1) is a rare CNS disorder caused by loss of orexin/hypocretin-producing neurons in the hypothalamus, patients experience excessive daytime sleepiness, cataplexy, sleep paralysis, hypnagogic hallucinations, disrupted nighttime sleep; the underlying biology — orexin deficiency — has made orexin replacement the long-pursued holy grail, but orexin peptides are large/cannot cross the BBB easily, so the race has been to develop small-molecule oral orexin-2 receptor agonists; ALKS 2680 — Alkermes's oral once-daily small-molecule orexin-2 receptor agonist in clinical development for NT1 (and potentially NT2 and idiopathic hypersomnia) — Phase 1 and Phase 1b/2 data have shown encouraging effects on wakefulness measures and tolerability, program moving toward Phase 2/3 trials and potential regulatory approval; the competitive landscape — Takeda's TAK-861 (oral orexin-2 receptor agonist) the most advanced competitor in the narcolepsy space with Phase 3 data anticipated (after the earlier TAK-994 program was discontinued for hepatic toxicity, TAK-861 has shown a cleaner profile), Centessa Pharmaceuticals (CNTA) ORX750 in earlier development, Jazz Pharmaceuticals (JAZZ) selling current standard-of-care narcolepsy drugs (Xyrem/Xywav, Sunosi) and developing its own orexin program; FY2025 dynamics are ALKS 2680 Phase 2 trial data continuing to mature with multiple readouts expected, regulatory engagement underway, development advancing; FY2026 catalyst is ALKS 2680 Phase 2 results / Phase 3 initiation / regulatory pathway clarification (the major asymmetric value-creation event — a successful orexin-2 agonist with a clean safety profile could be transformative worth multiple billions in annual revenue across narcolepsy types), plus earlier-stage CNS pipeline programs in psychiatric/neurological/sleep targets; the post-Mural-spin pipeline — after the late-2023 Mural (MURA) oncology spin Alkermes refocused on a CNS-only pipeline; risks are ALKS 2680 Phase 2/3 failure (efficacy or safety/tolerability — orexin-2 agonists need clean liver/safety profile after TAK-994), Takeda TAK-861 first-to-market capturing the franchise, other orexin programs emerging, regulatory pathway uncertainty (narcolepsy a rare disease — orphan-drug designation and accelerated-approval potential exist), CNS R&D risk; comp set is Jazz Pharmaceuticals (JAZZ) the incumbent leader, Takeda (4502.T), Centessa (CNTA), Avadel (AVDL), Harmony Biosciences (HRMY) in narcolepsy/sleep, and broader CNS Axsome (AXSM), Sage (SAGE), Vanda (VNDA), Acadia (ACAD), Intra-Cellular (now J&J). The capital story: net-cash, shareholder-return-rich — recently-initiated/considered dividend (~$0-0.40/share annually — historically none, post-Mural and royalty monetization deploying cash via buybacks + exploring dividend), substantial share buybacks (~155-165M shares down from ~170M+ peak), substantial net cash (~$500-800M+ cash/marketable securities with minimal debt — Elan-merger debt substantially paid down/refinanced), strong FCF (high-margin commercial CNS + modest capex), capital priorities fund R&D (esp. ALKS 2680) → aggressive buybacks → possible dividend → bolt-on M&A or BD → maintain net cash, with cash deployment optionality ($500-800M+ war chest), pipeline R&D spending, and strategic-decision pace under Pops as principal considerations. At ~$28-42 per share on ~155-165M shares (~$4.5-7B equity, ~$3.7-6.2B EV given net-cash) ALKS trades at roughly ~10-15x P/E, ~7-12x EV/EBITDA and ~10-15x EV/FCF — discounted versus where high-growth specialty pharmas trade, reflecting VIVITROL/ARISTADA maturity and modest LYBALVI visibility, but substantial ALKS 2680 upside if it delivers and FCF/balance-sheet downside protection — versus CNS Bristol-Myers (BMY, Cobenfy), Otsuka (4578.T), Lundbeck (LUN.CO), Axsome (AXSM), Sage (SAGE), Vanda (VNDA), Acadia (ACAD), Intra-Cellular (now J&J), narcolepsy Jazz (JAZZ), Avadel (AVDL), Harmony (HRMY), and broader specialty Insmed (INSM), Krystal Biotech (KRYS), Argenx (ARGX), Ultragenyx (RARE), BridgeBio (BBIO). FY2026 base case: ~$1.6-1.9B+ revenue + ~$3.00-3.75 adj. EPS + ~$400-490M adjusted EBITDA + LYBALVI growing + VIVITROL/ARISTADA stable + ALKS 2680 Phase 2 data + continued buybacks + cash building; bull case: ~$1.75-2.1B+ revenue + ~$3.50-4.50+ adj. EPS on stronger LYBALVI growth, share defense, ALKS 2680 Phase 2 clean and supporting Phase 3 / accelerated-approval (major asymmetric upside), accretive M&A, accelerated buybacks, and a re-rating; bear case: ~$1.45-1.65B revenue + ~$2.40-2.90 adj. EPS on a Cobenfy/competitor-take-share scenario, ALKS 2680 failure, Takeda TAK-861 first-to-market, pipeline disappointment, and a compression. The thesis depends on the commercial-CNS pipeline (VIVITROL + ARISTADA + LYBALVI trajectory + payer access + competitive positioning vs Cobenfy and generics) plus the ALKS 2680 + pipeline pipeline (Phase 2 data + Phase 3 path + competitive race with Takeda TAK-861 + broader CNS pipeline) plus the net-cash balance sheet plus aggressive buybacks plus possible bolt-on M&A plus Richard Pops's continued strategic stewardship.

[ALKS] Alkermes Thesis 2026: A CNS Pure-Play Pivots Toward Narcolepsy and an Orexin-Class Catalyst

Key Takeaways

Alkermes plc (NASDAQ: ALKS) is expected to close FY2025 with selected various aggregate revenue of roughly $1.55-1.85B (~mid-single-to-low-double-digit % growth) and aggregate adjusted EPS in the area of $2.80-3.50, with adjusted EBITDA around ~$380-470M (~22-26% margin), under Chairman, President & CEO Richard Pops (~35+ year tenure as founder/CEO since 1991, an unusually long-tenured biotech executive who has guided Alkermes through multiple strategic transformations).
The first deep-dive — the commercial CNS franchise — covers Alkermes's three approved central-nervous-system products: VIVITROL (extended-release naltrexone, ~once-monthly IM injection, for opioid and alcohol dependence — selected various aggregate ~$430-490M+ annual revenue), ARISTADA (long-acting aripiprazole, monthly/bi-monthly/every-2-month IM injection, for schizophrenia — ~$330-400M+), and LYBALVI (oral olanzapine/samidorphan combination for schizophrenia and bipolar, designed to address olanzapine's weight-gain side-effect — ~$310-400M+ and growing fastest); FY2026 catalyst is LYBALVI prescription growth, VIVITROL/ARISTADA share defense, and continued operating-margin expansion.
The second deep-dive — ALKS 2680 (the orexin-2 receptor agonist for narcolepsy) plus the pipeline beyond — covers the post-2023 transformation to a pure-play CNS company (after spinning off oncology programs as Mural Oncology in late 2023) plus the headline pipeline asset ALKS 2680 — an oral once-daily small-molecule orexin-2 receptor agonist for narcolepsy type 1 (NT1) — competing with Takeda's TAK-861/TAK-994 and other orexin agonists racing for a transformative-for-narcolepsy mechanism; FY2026 catalyst is ALKS 2680 Phase 2 / Phase 3 data and any regulatory interactions, plus other pipeline programs.
Capital position is net-cash and shareholder-return-friendly: a recently-initiated dividend (selected various aggregate ~$0-0.40/share annually — Alkermes has begun returning capital following the Mural spin and royalty divestitures), substantial buybacks (the diluted share count has declined from ~170M+ to selected various aggregate ~155-165M), substantial net cash (selected various aggregate ~$500-800M+ cash with minimal debt), no leverage of consequence, and ~155-165M shares outstanding (declining).
FY2026 catalysts: VIVITROL/ARISTADA/LYBALVI commercial performance (especially LYBALVI's continued rapid growth as the long-tail-of-launch dynamic plays out), ALKS 2680 clinical data (Phase 2 results, potential Phase 3 initiation or regulatory pathway — the major value-creation event), pipeline data (other CNS programs), the next major M&A or business-development move (Alkermes has been deploying its cash strategically), and continued buybacks.

Company Background

Alkermes plc, headquartered in Dublin, Ireland (with US operations principally in Waltham, Massachusetts), is a biopharmaceutical company focused on central-nervous-system (CNS) diseases — developing and commercializing therapies for psychiatric conditions (schizophrenia, bipolar disorder), addiction (opioid and alcohol dependence), and sleep/wakefulness disorders (narcolepsy). The company was founded in 1987 by Richard Pops (Chairman, President & CEO — one of the longest-tenured CEOs in biotech) and has evolved over decades through multiple strategic transformations: a 1990s/2000s focus on drug-delivery technology (the long-acting injectable / sustained-release platforms that underpin VIVITROL and ARISTADA), a 2011 reverse merger with Elan Drug Technologies that established the current Irish-headquartered structure, a multi-year build of a commercial-stage CNS franchise (VIVITROL launched 2006, ARISTADA 2015, LYBALVI 2021), an oncology-development push that was spun off in late 2023 as Mural Oncology (MURA) to refocus Alkermes as a pure-play CNS company, and the 2022-2024 monetization of various royalty streams (including the Sandoz/Aristada-related royalties) generating substantial cash. Today Alkermes runs a focused commercial CNS portfolio plus a CNS-focused pipeline, with the headline pipeline asset ALKS 2680 — an oral orexin-2 receptor agonist for narcolepsy. The capital structure is net-cash with minimal debt, and the company has begun returning capital aggressively via buybacks (and a recently-initiated/possible small dividend). Geography is US-led commercial with selected ex-US partnered. Risks: commercial CNS competition (newer schizophrenia/depression agents — Bristol-Myers's Cobenfy for schizophrenia, Otsuka's Rexulti, broader generic-aripiprazole pressure), VIVITROL/ARISTADA/LYBALVI commercial pricing/payer dynamics, ALKS 2680 Phase 2/3 trial outcome (a meaningful binary), competing orexin programs (especially Takeda's TAK-861), CNS R&D risk generally, and the long-term Pops-succession question (he's been CEO for 35+ years).

The Commercial CNS Franchise: VIVITROL, ARISTADA, and LYBALVI

The commercial franchise is three approved CNS products that together generate selected various aggregate ~$1.1-1.3B+ of annual revenue — the bulk of Alkermes's revenue and the cash engine. VIVITROL (extended-release naltrexone, ~once-monthly intramuscular injection): launched 2006, VIVITROL is an opioid-antagonist depot injection for the treatment of opioid dependence and alcohol dependence — administered once monthly, providing sustained naltrexone blockade that prevents opioid effect and reduces alcohol craving; the drug is used in addiction-treatment centers, behavioral-health clinics, drug courts, prison systems, and (increasingly) primary-care and OBGYN settings; selected various aggregate ~$430-490M+ annual revenue and growing low-single-digit % — historical growth driven by the opioid epidemic, addiction-treatment-system expansion, and the LAI-injection advantage vs daily oral naltrexone. ARISTADA (aripiprazole lauroxil, long-acting injectable — monthly, bi-monthly, or every-2-month options): launched 2015, ARISTADA is a long-acting injectable antipsychotic (LAI) for schizophrenia — a once-monthly-or-longer alternative to daily oral aripiprazole that improves treatment adherence; selected various aggregate ~$330-400M+ annual revenue and growing low-to-mid-single-digit % — competing in the schizophrenia LAI market against Otsuka/Lundbeck's Abilify Maintena (also aripiprazole, monthly), Otsuka's Aristada (now Alkermes — overlapping name initially), Janssen's Invega Sustenna/Trinza/Hafyera (paliperidone), Sandoz's Risperdal Consta (risperidone), and various generic options; ARISTADA differentiates on dosing intervals (the every-2-month option) and a unique aripiprazole-lauroxil pro-drug profile. LYBALVI (olanzapine/samidorphan combination, oral once-daily): launched 2021, LYBALVI is oral olanzapine combined with samidorphan (an opioid antagonist) — designed to provide olanzapine's strong antipsychotic efficacy for schizophrenia and bipolar I disorder while reducing the substantial weight-gain side-effect that has historically limited olanzapine's use; selected various aggregate ~$310-400M+ annual revenue and growing fastest in the portfolio (mid-teens to high-twenties %) as the long-tail-of-launch dynamic plays out, addressing a real unmet need (olanzapine is the most efficacious oral antipsychotic but its weight gain is a major adherence barrier). FY2025 dynamics: VIVITROL and ARISTADA growing steadily, LYBALVI accelerating, gross-to-net stabilizing across the portfolio, operating leverage improving as marketing/SG&A grows slower than revenue. FY2026 catalyst: LYBALVI prescription growth (the leading-edge driver), VIVITROL/ARISTADA share defense, payer/formulary dynamics, generic-aripiprazole competitive pressure on ARISTADA, and continued operating-margin expansion. Risks/competitors: generic competition (the LAI mechanisms partially insulate ARISTADA and VIVITROL from oral generics, but pricing pressure persists), newer antipsychotic agents (Bristol-Myers's Cobenfy — KarXT/xanomeline-trospium for schizophrenia, approved 2024 — a new-mechanism agent that's now competing), payer/formulary access pressure, addiction-treatment-system funding fluctuations, and the broader CNS competitive set — Bristol-Myers (BMY, Cobenfy), Otsuka (4578.T, Rexulti), Janssen/J&J (JNJ, Invega franchise), AbbVie (ABBV), Lundbeck (LUN.CO).

ALKS 2680 (Orexin-2 Receptor Agonist for Narcolepsy) Plus the Broader Pipeline

The second deep-dive is ALKS 2680 plus the rest of the post-Mural-spin pipeline — the growth optionality that frames the equity. The narcolepsy opportunity: narcolepsy type 1 (NT1) is a rare CNS disorder caused by loss of orexin/hypocretin-producing neurons in the hypothalamus — patients experience excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), sleep paralysis, hypnagogic hallucinations, and disrupted nighttime sleep; the underlying biology — orexin deficiency — has made orexin replacement the long-pursued holy grail for narcolepsy treatment, but the orexin peptides themselves are large/can't cross the blood-brain barrier easily, so the race has been to develop small-molecule oral orexin-2 receptor agonists that can replace the missing orexin signaling. ALKS 2680: Alkermes's oral, once-daily small-molecule orexin-2 receptor agonist in clinical development for narcolepsy type 1 (and potentially type 2 and idiopathic hypersomnia) — Phase 1 and Phase 1b/2 data have shown encouraging effects on wakefulness measures and tolerability; the program is moving toward Phase 2/3 trials and potential regulatory approval. The competitive landscape: Takeda's TAK-861 (an oral orexin-2 receptor agonist) is the most advanced competitor in the narcolepsy space with Phase 3 data anticipated (after the earlier TAK-994 program was discontinued for hepatic toxicity, TAK-861 has shown a cleaner profile); Centessa Pharmaceuticals (CNTA) has ORX750 in earlier development; Jazz Pharmaceuticals (JAZZ) sells the current standard-of-care narcolepsy drugs (Xyrem/Xywav, Sunosi) and has its own orexin program in development. FY2025 dynamics: ALKS 2680 Phase 2 trial data continuing to mature (with multiple data readouts expected), regulatory engagement underway, development advancing. FY2026 catalyst: ALKS 2680 Phase 2 results / Phase 3 initiation / regulatory pathway clarification — the major asymmetric value-creation event (a successful orexin-2 agonist with a clean safety profile could be a transformative product worth multiple billions in annual revenue across narcolepsy types), plus other earlier-stage pipeline programs (CNS-focused — selected various aggregate including programs in psychiatric, neurological and sleep-disorder targets). The post-Mural-spin pipeline: after the late-2023 spin-off of oncology programs as Mural Oncology (MURA), Alkermes refocused on a CNS-only pipeline of multiple earlier-stage programs targeting psychiatric and neurological conditions. FY2025 dynamics: pipeline programs progressing, with ALKS 2680 the headline asset. FY2026 catalyst: ALKS 2680 data is the big binary, with other pipeline data adding incremental value. Risks: ALKS 2680 Phase 2/3 trial failure (efficacy or safety/tolerability — orexin-2 agonists need a clean liver/safety profile after TAK-994's discontinuation), Takeda TAK-861 reading out first and capturing first-mover advantage, other orexin programs emerging, regulatory pathway uncertainty (narcolepsy is a rare disease — orphan-drug designation and accelerated-approval potential exist but are not guaranteed), and CNS R&D risk generally. Comp set: in narcolepsy/sleep — Jazz Pharmaceuticals (JAZZ, the incumbent leader), Takeda (4502.T), Centessa Pharmaceuticals (CNTA), Avadel (AVDL), Harmony Biosciences (HRMY); in CNS broadly — Vanda (VNDA), Sage Therapeutics (SAGE), Axsome (AXSM), Ironwood (IRWD), Insmed (INSM), Ultragenyx (RARE).

Capital Position + Balance Sheet

Alkermes runs a net-cash, shareholder-return-rich balance sheet — a notable evolution from earlier years when the company was R&D-investment-heavy. The company has recently initiated or is considering a regular dividend (selected various aggregate ~$0-0.40/share annually — Alkermes has historically not paid a dividend but post-Mural and royalty monetization has been deploying cash via buybacks and exploring incremental dividend), conducts substantial share buybacks (the diluted share count has fallen from selected various aggregate ~170M+ at peak to ~155-165M and continues to decline at meaningful pace), and holds substantial net cash (selected various aggregate ~$500-800M+ of cash and marketable securities with minimal debt — the legacy Elan-merger debt has been substantially paid down or refinanced, leaving the company essentially net-cash). Free-cash-flow conversion is strong (a high-margin commercial CNS business with modest capex). Capital priorities: fund R&D (especially ALKS 2680 development) → aggressive share buybacks → potential dividend → bolt-on M&A or business development → maintain net cash. The principal balance-sheet considerations are the cash deployment optionality (a $500-800M+ war chest for accretive M&A or further buybacks), pipeline R&D spending, and the strategic-decision pace under Pops.

Key Core Metrics

Revenue: selected various aggregate ~$1.55-1.85B FY2025 (~mid-single-to-low-double-digit % growth)
Adjusted EBITDA: selected various aggregate ~$380-470M FY2025 (~22-26% margin)
Adjusted EPS: selected various aggregate ~$2.80-3.50 FY2025
Free cash flow: selected various aggregate ~$300-450M FY2025
VIVITROL (extended-release naltrexone, monthly IM): opioid/alcohol dependence; ~$430-490M+ annual; low-single-digit % growth; launched 2006
ARISTADA (aripiprazole lauroxil, monthly/bi-monthly/every-2-month LAI): schizophrenia; ~$330-400M+ annual; low-to-mid-single-digit % growth; launched 2015
LYBALVI (oral olanzapine/samidorphan combination, once-daily): schizophrenia + bipolar I; ~$310-400M+ annual; mid-teens-to-twenties % growth (long-tail-of-launch); launched 2021
Differentiation: VIVITROL & ARISTADA = long-acting injectable (LAI) adherence advantage; LYBALVI = olanzapine efficacy without the weight-gain side-effect
Competitive set in schizophrenia: Bristol-Myers's Cobenfy (KarXT, approved 2024 — new mechanism), Otsuka/Lundbeck's Rexulti and Abilify Maintena (aripiprazole LAI), Janssen Invega franchise, AbbVie, generics
ALKS 2680: oral once-daily orexin-2 receptor agonist for narcolepsy type 1 (and potentially NT2/idiopathic hypersomnia); Phase 2 data maturing; Phase 3 path being established
Narcolepsy opportunity: orexin-deficiency-driven; large unmet need; small-molecule orexin agonists are the "holy grail"
Orexin-program competitors: Takeda TAK-861 (most advanced, Phase 3 anticipated), Centessa CNTA's ORX750, Jazz's program
Mural Oncology spin: late 2023 spin-off of oncology programs as Mural (MURA); Alkermes refocused as pure-play CNS
Pipeline (other): multiple earlier-stage CNS programs (psychiatric, neurological, sleep)
Geography: US-led commercial; selected ex-US partnered
Cash + marketable securities: selected various aggregate ~$500-800M+ (minimal debt — essentially net-cash)
Net debt: net cash (no meaningful debt; legacy substantially paid down/refinanced)
Credit profile: implicitly investment-grade-equivalent (unrated/minimally rated)
Dividend: selected various aggregate ~$0-0.40/share annually (recently initiated or under consideration; historically none)
Buybacks: aggressive ongoing; diluted share count ~155-165M (down from ~170M+ peak)
Capex: modest; strong FCF conversion
Capital allocation: R&D (especially ALKS 2680) → aggressive buybacks → possible dividend → bolt-on M&A → maintain net cash
CEO: Richard Pops (Chairman, President & CEO; ~35+ year tenure — founder, since 1991)
Domicile: Dublin, Ireland (US operations Waltham, MA)

Market Evaluation

At roughly ~$28-42 per share on ~155-165M shares, Alkermes carries an equity value of selected various aggregate ~$4.5-7B (and an enterprise value of selected various aggregate ~$3.7-6.2B given the net-cash position), which on FY2025 cash flow is roughly ~10-15x P/E, ~7-12x EV/EBITDA and ~10-15x EV/FCF — a multiple discounted versus where high-growth specialty pharmas trade, reflecting the maturity of the VIVITROL/ARISTADA franchise plus modest LYBALVI growth visibility, but with substantial upside if ALKS 2680 delivers (and the cash flow / balance sheet provides downside protection). The comp set: in CNS specialty pharma — Bristol-Myers (BMY, Cobenfy in schizophrenia + broader), Otsuka (4578.T), Lundbeck (LUN.CO), Axsome Therapeutics (AXSM), Sage Therapeutics (SAGE), Vanda Pharmaceuticals (VNDA), Acadia Pharmaceuticals (ACAD), Intra-Cellular Therapies (ITCI — now Johnson & Johnson); in narcolepsy/sleep — Jazz Pharmaceuticals (JAZZ), Avadel (AVDL), Harmony Biosciences (HRMY); in broader specialty/biopharma — Insmed (INSM), Krystal Biotech (KRYS), Argenx (ARGX), Ultragenyx (RARE), BridgeBio (BBIO). FY2026 base case: selected various aggregate ~$1.6-1.9B+ revenue + ~$3.00-3.75 adj. EPS + ~$400-490M adjusted EBITDA + LYBALVI continuing to grow + VIVITROL/ARISTADA stable + ALKS 2680 Phase 2 data flowing + continued buybacks + cash building. Bull case: selected various aggregate ~$1.75-2.1B+ revenue + ~$3.50-4.50+ adj. EPS on stronger LYBALVI growth (long-tail-of-launch continuing), VIVITROL/ARISTADA share defense, ALKS 2680 Phase 2 data clean and supporting Phase 3 / accelerated-approval discussions (the major asymmetric upside event), accretive M&A deploying the cash pile, accelerated buybacks, and a multiple re-rating toward CNS-specialty-pharma peers. Bear case: selected various aggregate ~$1.45-1.65B revenue + ~$2.40-2.90 adj. EPS on a Cobenfy/competitor-take-share scenario in schizophrenia (compressing ARISTADA/LYBALVI), ALKS 2680 Phase 2 failure or safety signal, Takeda TAK-861 first-to-market in narcolepsy (capturing the franchise opportunity), pipeline disappointment, and a multiple compression. The thesis turns on the commercial-CNS pipeline (VIVITROL + ARISTADA + LYBALVI revenue trajectory + payer-access dynamics + competitive positioning vs Cobenfy and generics) plus the ALKS 2680 + pipeline pipeline (Phase 2 data + Phase 3 path + competitive race with Takeda's TAK-861 + the broader CNS pipeline) plus the net-cash balance sheet plus aggressive buybacks plus possible bolt-on M&A plus Richard Pops's continued strategic stewardship of the post-Mural pure-play CNS Alkermes.